Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Solid Tumors 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 24Vincristine 17Prednisone 16Methotrexate 16prednylidene 13merphos 13deltacortene 13blinatumomab 13Specimen Handling 13Cytarabine 13pegaspargase 10N,N-dicyclohexyl-isoborneol-10-sulfonamide 10Mercaptopurine 10Doxorubicin 10Dexamethasone 10Biopsy 10azathiopurine 9Spinal Puncture 9Etoposide 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Rituximab 8Leucovorin 8Calcium Dobesilate 8venetoclax 7fludarabine 7Asparaginase 7Thioguanine 6Magnetic Resonance Spectroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × pegylated granulocyte colony-stimulating factor × 30 days × Clear all
NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡